2012;five(3):141-7. 76. Frye RE, Melnyk S, MacFabe DS. Exceptional acyl-carnitine profiles are possible biomarkers for acquired mitochondrial disease in autism spectrum disorder. Transl Psychiatry. 2013;three:e220. doi:ten.1038/tp.2012.143. 77. Jones LL, McDonald DA, Borum PR. Acylcarnitines: function in brain. Prog Lipid Res. 2010;49(1):61-75. 78. Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deficiency in autism. J Autism Dev Disord. 2004;34(six):615-23. 79. Celestino-Soper PB, Violante S, Crawford EL, et al. A typical X-linked inborn error of carnitine biosynthesis may be a danger issue for nondysmorphic autism. Proc Nat journal.pone.0077579 Acad Sci U S A. 2012;109(21):7974-81. 80. Pochini L, Galluccio M, Scumaci D, et al. Interaction of beta-lactam antibiotics with the mitochondrial carnitine/acylcarnitine transporter. Chem Biol Interact. 2008;173(3):187-94. 81. Berk M, Malhi GS, Gray LJ, Dean OM. The GW0918 promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci. 2013;34(3):167-77. 82. El-Ansary AK, Ben BA, Kotb M. Etiology of autistic attributes: the persisting neurotoxic effects of propionic acid. J Neuroinflammation. 2012;9(1):74. 83. El-Ansary A, Al-Daihan S, Al-Dbass A, Al-Ayadhi L. Measurement of selected ions connected to oxidative anxiety and energy metabolism in Saudi autistic kids. Clin Biochem. 2010;43(1-2):63-70. 84. Al-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L. Metabolic biomarkers connected to oxidative pressure and antioxidant status in Saudi autistic children. Clin Biochem. 2009;42(10-11):1032-40. 85. Gottschall E. Breaking the vicious cycle: intestinal wellness by way of diet. Baltimore, Ontario, Canada: The Kirkton Press; 1994. 86. Frye RE, Rossignol DA. Mitochondrial dysfunction can connect the diverse medical symptoms related with autism spectrum disorders. Pediatr Res. 2011;69:41R-47-R. 87. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum problems: a systematic review and meta-analysis. Mol Psychiatry. 2011 Jan 25;17:290-314. 88. Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Elevated fecal short chain fatty acid geronb/gbp074 and ammonia concentrations in children with autism spectrum disorder. Dig Dis Sci. 2012 Aug;57(8):2096-102. 89. Williams BL, Hornig M, Buie T, et al. Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of young children with autism and gastrointestinal disturbances. PLoS One. 2011;six(9):e24585. 90. Saulnier DM, Ringel Y, Heyman MB, et al. The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. Gut Microbes. 2013;four(1):17-27. 91. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact from the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(ten):701-12. 92. Cho I, Yamanishi S, Cox L, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012;488(7413):621-6. 93. Petrof EO, Claud EC, Gloor GB, Allen-Vercoe E. Microbial ecosystems therapeutics: a brand new paradigm in medicine? Benef Microbes. 2013;four(1):53-65. 94. White RA, Bjornholt JV, Baird DD, et al. Novel developmental analyses recognize longitudinal patterns of early gut microbiota that have an effect on infant development.